Jean-François Dhainaut Selected Research

drotrecogin alfa activated (Xigris)

5/2012	Drotrecogin alfa (activated) in adults with septic shock.
11/2008	Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.
4/2008	International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
1/2008	Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
1/2007	Cost-effectiveness of activated protein C in real-life clinical practice.
5/2004	Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis.
10/2003	Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
9/2003	The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.
6/2003	Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
1/2003	Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-François Dhainaut Research Topics

Disease

19	Sepsis (Septicemia) 01/2009 - 05/2002
5	Septic Shock (Toxic Shock Syndrome) 05/2012 - 01/2003
4	Hemorrhage 01/2007 - 01/2003
3	Infections 03/2005 - 01/2003
3	Inflammation (Inflammations) 04/2004 - 05/2002
2	Multiple Organ Failure (MODS) 01/2007 - 06/2003
2	Heart Arrest (Cardiac Arrest) 08/2005 - 07/2002
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 04/2003 - 04/2003
2	Acute Lung Injury 04/2003 - 04/2003
1	Pneumonia (Pneumonitis) 01/2009
1	Acute Kidney Injury (Acute Renal Failure) 07/2006
1	Critical Illness (Critically Ill) 07/2006
1	Ventricular Fibrillation 08/2005
1	Hypothermia 08/2005
1	Out-of-Hospital Cardiac Arrest 08/2005
1	Disseminated Intravascular Coagulation 03/2005
1	Thrombosis (Thrombus) 03/2005
1	Hypercapnia 01/2005
1	Hypoxia (Hypoxemia) 01/2005
1	Communicable Diseases (Infectious Diseases) 11/2004
1	Purpura Fulminans 05/2004
1	Cross Infection (Nosocomial Infection) 04/2004
1	Urinary Tract Infections (Urinary Tract Infection) 09/2003
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 04/2003
1	Lung Injury 04/2003
1	Lactic Acidosis 04/2003
1	Pulmonary Edema 04/2003
1	Hypotension (Low Blood Pressure) 12/2002

Drug/Important Bio-Agent (IBA)

11	drotrecogin alfa activated (Xigris)FDA Link 05/2012 - 12/2002
9	Protein CIBA 05/2012 - 05/2002
3	AnticoagulantsIBA 04/2003 - 05/2002
2	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2009 - 04/2003
2	Biomarkers (Surrogate Marker)IBA 04/2004 - 10/2003
2	ThrombomodulinIBA 04/2003 - 05/2002
2	Thrombin FDA Link 04/2003 - 05/2002
1	Dobutamine FDA LinkGeneric 05/2008
1	Adrenergic Agents (Adrenergic Drugs)IBA 05/2008
1	Catalytic AntibodiesIBA 03/2005
1	Factor VIII (Coagulation Factor VIII)IBA 03/2005
1	Immunoglobulin G (IgG)IBA 03/2005
1	Factor IX (Coagulation Factor IX)FDA LinkGeneric 03/2005
1	Serine Proteases (Serine Protease)IBA 03/2005
1	fibrin fragment D (D-dimer)IBA 05/2004
1	Brain Natriuretic Peptide (Natrecor)FDA Link 03/2004
1	Pharmaceutical PreparationsIBA 06/2003
1	Escherichia coli endotoxinIBA 04/2003
1	Transforming Growth Factors (Transforming Growth Factor)IBA 04/2003
1	IntegrinsIBA 04/2003
1	Lactic Acid (Lactate)FDA LinkGeneric 04/2003
1	Carnitine (L-Carnitine)FDA LinkGeneric 04/2003
1	Bleomycin (Blenoxane)FDA LinkGeneric 04/2003
1	AntithrombinsIBA 04/2003
1	Transforming Growth Factor beta (TGF-beta)IBA 04/2003
1	NucleosidesIBA 04/2003
1	Heparin (Liquaemin)FDA LinkGeneric 04/2003
1	CytokinesIBA 07/2002
1	EndotoxinsIBA 07/2002
1	Fibrinogen (Factor I)FDA Link 05/2002

Therapy/Procedure

6	Therapeutics 01/2009 - 01/2003
4	Critical Care (Surgical Intensive Care) 01/2009 - 05/2002
2	Hemofiltration 08/2005 - 11/2004
2	Artificial Respiration (Mechanical Ventilation) 01/2005 - 04/2004
1	Continuous Renal Replacement Therapy 07/2006
1	Resuscitation 12/2002
1	Cardiopulmonary Resuscitation (CPR) 07/2002